IS therapy plus HCQ N = 26 | Conventional IS therapy N = 26 | P-value | |
---|---|---|---|
Gender | |||
Male/female | 9/17 | 10/16 | 0.773 |
Age at renal biopsy (years) | 28.8 ± 10.2 | 30.8 ± 12.2 | 0.522 |
Duration of IS therapy before HCQ/other IS agents (months) | 7.4 (4.9,10.8) | 3.9 (2.1,11.3) | 0.079 |
Proteinuria level before IS therapy (g/d) | 2.52 (1.66,5.60) | 2.27 (1.54,4.36) | 0.727 |
Baseline proteinuria (g/d) | 2.35 (1.47,2.98) | 2.35 (1.54,2.98) | 0.920 |
Baseline eGFR (ml/min/1.73 m2) | 47.65 (34.65,67.48) | 51.59 (26.47,82.32) | 0.855 |
Oxford Classification | |||
M 0/1 | 2/21 | 9/17 | 0.030 |
E 0/1 | 11/12 | 14/12 | 0.674 |
S 0/1 | 7/16 | 15/11 | 0.056 |
T 0/1/2 | 3/18/2 | 11/11/4 | 0.034 |
C 0/1/2 | 5/15/3 | 10/16/0 | 0.104 |
RAASi therapy | 25 | 22 | |
ACEI alone | 14 | 4 | |
ARB alone | 11 | 6 | |
ACEI plus ARB | 0 | 12 | |
Use of statins | 6 | 8 | |
Corticosteroid treatment | |||
Corticosteroid pulse therapy | 13 | 8 | |
Oral corticosteroids | 13 | 18 | |
Immunosuppressive agents | 14/26 | 26/26 | |
Cyclophosphamide | 6 | 14 | |
Mycophenolate mofetil | 3 | 3 | |
Cyclosporine A | 2 | 4 | |
Leflunomide | 2 | 4 | |
FK506 | 1 | 1 |